Published in J Exp Med on December 01, 2003
Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest (2004) 5.16
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol (2008) 3.37
Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol (2013) 2.89
Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci U S A (2005) 2.83
Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol (2009) 2.79
The burgeoning family of unconventional T cells. Nat Immunol (2015) 2.70
Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells. Proc Natl Acad Sci U S A (2006) 2.34
Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol (2012) 2.32
A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells. Immunity (2011) 2.11
The role of NKT cells in tumor immunity. Adv Cancer Res (2008) 2.05
A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity (2014) 2.02
Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity (2009) 2.00
Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest (2007) 1.83
Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J Immunol (2009) 1.81
Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A (2006) 1.74
Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci U S A (2007) 1.62
The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest (2004) 1.61
The T cell antigen receptor expressed by Valpha14i NKT cells has a unique mode of glycosphingolipid antigen recognition. Proc Natl Acad Sci U S A (2004) 1.61
Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. J Clin Invest (2010) 1.60
Functionally distinct NKT cell subsets and subtypes. J Exp Med (2005) 1.54
Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin Immunol (2009) 1.44
Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. EMBO J (2011) 1.43
Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med (2005) 1.31
Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen alphaGalCer. Proc Natl Acad Sci U S A (2009) 1.31
Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci U S A (2005) 1.29
Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest (2007) 1.28
Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. J Immunol (2008) 1.26
Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res (2010) 1.25
Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J Immunol (2009) 1.18
Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers. Eur J Immunol (2008) 1.18
Distinct APCs explain the cytokine bias of α-galactosylceramide variants in vivo. J Immunol (2012) 1.15
Distinct and overlapping effector functions of expanded human CD4+, CD8α+ and CD4-CD8α- invariant natural killer T cells. PLoS One (2011) 1.14
NKT cell networks in the regulation of tumor immunity. Front Immunol (2014) 1.13
Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells. Immunology (2009) 1.12
Natural killer T-cell autoreactivity leads to a specialized activation state. Blood (2008) 1.11
Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis. PLoS Pathog (2008) 1.11
Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders. Gut (2007) 1.10
NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood (2012) 1.09
Glycolipids as immunostimulating agents. Bioorg Med Chem (2007) 1.09
Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res (2012) 1.08
Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J Immunol Methods (2009) 1.07
Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency. J Immunol (2010) 1.07
Glycolipids that elicit IFN-γ-biased responses from natural killer T cells. Chem Biol (2011) 1.05
Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine (2009) 1.05
Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity. J Clin Invest (2011) 1.03
Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production. J Am Chem Soc (2008) 1.01
NKT TCR recognition of CD1d-α-C-galactosylceramide. J Immunol (2011) 0.99
Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells. Immunol Rev (2012) 0.99
Human natural killer T cells are heterogeneous in their capacity to reprogram their effector functions. PLoS One (2006) 0.97
Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS One (2012) 0.97
Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol (2010) 0.96
Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Front Biosci (Landmark Ed) (2009) 0.96
Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity. Vaccine (2009) 0.96
Regulation of the actin cytoskeleton by Rho kinase controls antigen presentation by CD1d. J Immunol (2012) 0.96
The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res (2015) 0.96
Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am J Respir Crit Care Med (2010) 0.94
Natural killer T cells in health and disease. Front Biosci (Schol Ed) (2011) 0.94
Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells. Proc Natl Acad Sci U S A (2013) 0.94
Optimizing NKT cell ligands as vaccine adjuvants. Immunotherapy (2014) 0.93
Α-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents. PLoS One (2010) 0.93
How do natural killer T cells help B cells? Expert Rev Vaccines (2009) 0.92
Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ. PLoS One (2011) 0.91
Harnessing CD1d-restricted T cells toward antitumor immunity in humans. Ann N Y Acad Sci (2009) 0.91
Stimulation of natural killer T cells by glycolipids. Molecules (2013) 0.91
Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol (2008) 0.89
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents. Clin Transl Immunology (2016) 0.88
A rapid fluorescence-based assay for classification of iNKT cell activating glycolipids. J Am Chem Soc (2011) 0.88
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. PLoS One (2013) 0.86
Diverse roles of non-diverse molecules: MHC class Ib molecules in host defense and control of autoimmunity. Curr Opin Immunol (2010) 0.86
Cytokine dependent and independent iNKT cell activation. Cytokine (2010) 0.86
Structural and functional characterization of a novel nonglycosidic type I NKT agonist with immunomodulatory properties. J Immunol (2012) 0.86
Invariant NKT cells as novel targets for immunotherapy in solid tumors. Clin Dev Immunol (2012) 0.86
A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity. Semin Immunol (2009) 0.86
Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants. Expert Rev Vaccines (2008) 0.86
Targeting the diverse immunological functions expressed by hepatic NKT cells. Expert Opin Ther Targets (2011) 0.86
Alpha-S-GalCer: synthesis and evaluation for iNKT cell stimulation. Bioorg Med Chem Lett (2008) 0.85
Strategy of lipid recognition by invariant natural killer T cells: 'one for all and all for one'. Immunology (2012) 0.84
A multifactorial mechanism in the superior antimalarial activity of alpha-C-GalCer. J Biomed Biotechnol (2009) 0.84
Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production. ACS Chem Biol (2012) 0.83
Alpha-galactosylceramide promotes killing of Listeria monocytogenes within the macrophage phagosome through invariant NKT-cell activation. Infect Immun (2010) 0.83
Synthesis of a versatile building block for the preparation of 6-N-derivatized α-galactosyl ceramides: rapid access to biologically active glycolipids. J Org Chem (2010) 0.83
Toll-like receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes. Sci Rep (2013) 0.82
Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. PLoS One (2014) 0.82
The Alpha and Omega of Galactosylceramides in T Cell Immune Function. J Biol Chem (2015) 0.82
The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8(+) T Cell Generation. Front Immunol (2015) 0.80
Activation of natural killer T cells by α-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis. Clin Exp Immunol (2011) 0.80
Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. Clin Exp Immunol (2011) 0.80
Invariant natural killer T cells and their ligands: focus on multiple sclerosis. Immunology (2015) 0.80
Selective Conditions Are Required for the Induction of Invariant NKT Cell Hyporesponsiveness by Antigenic Stimulation. J Immunol (2015) 0.79
NK and NKT Cell Depletion Alters the Outcome of Experimental Pneumococcal Pneumonia: Relationship with Regulation of Interferon-γ Production. J Immunol Res (2015) 0.79
Natural killer T cells subsets in cancer, functional defects in prostate cancer and implications for immunotherapy. Cancers (Basel) (2011) 0.79
Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric α-galactosyl ceramide analogues. Carbohydr Res (2012) 0.79
Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants. Front Biol (Beijing) (2012) 0.78
Invariant natural killer T cells in rheumatic disease: a joint dilemma. Nat Rev Rheumatol (2010) 0.78
C-Galactosylceramide: Synthesis and Immunology. C R Chim (2012) 0.78
Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses. Oncoimmunology (2015) 0.78
Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice. Oncoimmunology (2015) 0.77
Lipid and Carbohydrate Modifications of α-Galactosylceramide Differently Influence Mouse and Human Type I Natural Killer T Cell Activation. J Biol Chem (2015) 0.77
Engagement of glycosylphosphatidylinositol-anchored proteins results in enhanced mouse and human invariant natural killer T cell responses. Immunology (2010) 0.77
CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science (1997) 13.67
Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science (1997) 8.95
Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol (1997) 7.76
Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 7.52
Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med (2000) 6.15
Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol (1999) 5.86
A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature (2001) 5.08
NKT cells: facts, functions and fallacies. Immunol Today (2000) 4.40
CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med (1998) 4.15
Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. Immunity (1997) 3.74
Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol (2002) 3.61
Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol (1996) 3.59
Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int J Parasitol (2001) 3.51
Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol (2000) 2.99
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood (2002) 2.72
Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem (1995) 2.62
The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci U S A (2003) 2.62
alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci U S A (2000) 2.30
Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci U S A (2003) 2.28
Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation. J Immunol (2000) 1.79
A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol (1999) 1.69
Immunotherapy with ligands of natural killer T cells. Trends Mol Med (2002) 1.17
Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells. J Immunol (2001) 1.15
Requirement for IFN-gamma in IL-12 production induced by collaboration between v(alpha)14(+) NKT cells and antigen-presenting cells. Int Immunol (2000) 1.10
Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells. Vox Sang (2002) 1.06
Convergent C-glycolipid synthesis via the Ramberg-Bäcklund reaction: active antiproliferative glycolipids. Org Lett (1999) 0.85
Synthesis and growth inhibitory properties of glucosamine-derived glycerolipids. Org Lett (2001) 0.83
Synthesis of homoceramides, novel ceramide analogues, and their lack of effect on the growth of hippocampal neurons. J Org Chem (2002) 0.82
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Recognition of bacterial glycosphingolipids by natural killer T cells. Nature (2005) 6.38
Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol (2006) 5.51
Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol (2011) 3.48
A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med (2011) 2.78
Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med (2002) 2.38
Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci U S A (2005) 2.13
Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J Immunol (2009) 1.81
Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A (2006) 1.74
Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. J Clin Invest (2010) 1.60
Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J Am Chem Soc (2006) 1.47
Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. EMBO J (2011) 1.43
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A (2010) 1.37
The C-glycoside analogue of the immunostimulant alpha-galactosylceramide (KRN7000): synthesis and striking enhancement of activity. Angew Chem Int Ed Engl (2004) 1.31
Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci U S A (2011) 1.30
Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci U S A (2005) 1.29
Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. J Immunol (2008) 1.26
Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 gamma-secretase complexes. J Biol Chem (2008) 1.20
Efficient synthesis of alpha-C-galactosyl ceramide immunostimulants: use of ethylene-promoted olefin cross-metathesis. Org Lett (2004) 1.19
Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res (2007) 1.19
Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine (2008) 1.19
Diverted total synthesis leads to the generation of promising cell-migration inhibitors for treatment of tumor metastasis: in vivo and mechanistic studies on the migrastatin core ether analog. J Am Chem Soc (2010) 1.19
High-throughput identification of inhibitors of human mitochondrial peptide deformylase. J Biomol Screen (2007) 1.18
Cognitive dysfunction in mice infected with Plasmodium berghei strain ANKA. J Infect Dis (2008) 1.16
Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest (2010) 1.12
Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells. Immunology (2009) 1.12
Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res (2012) 1.08
Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J Immunol Methods (2009) 1.07
Endothelin in a murine model of cerebral malaria. Exp Biol Med (Maywood) (2006) 1.06
Stereoselective synthesis of photoreactive peptidomimetic gamma-secretase inhibitors. J Org Chem (2004) 1.06
Alpha-c-galactosylceramides: synthesis and immunology. Acc Chem Res (2006) 1.05
Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine (2009) 1.05
E and Z alpha-C-galactosylceramides by Julia-Lythgoe-Kocienski chemistry: a test of the receptor-binding model for glycolipid immunostimulants. Chembiochem (2006) 1.04
Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One (2011) 1.03
Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection. Int Immunol (2007) 1.03
Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine (2004) 1.02
Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production. J Am Chem Soc (2008) 1.01
NKT TCR recognition of CD1d-α-C-galactosylceramide. J Immunol (2011) 0.99
Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect Immun (2013) 0.99
Emergence of potent inhibitors of metastasis in lung cancer via syntheses based on migrastatin. Proc Natl Acad Sci U S A (2011) 0.97
A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner. J Immunol (2007) 0.97
Reduced cerebral blood flow and N-acetyl aspartate in a murine model of cerebral malaria. Parasitol Res (2005) 0.97
Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol (2010) 0.96
The dendritic cell-specific chemokine, dendritic cell-derived CC chemokine 1, enhances protective cell-mediated immunity to murine malaria. J Immunol (2003) 0.96
Carbohydrates and T cells: a sweet twosome. Semin Immunol (2013) 0.95
Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models. Phytother Res (2008) 0.94
A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J Immunol (2010) 0.93
Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites. Vaccine (2011) 0.92
Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells. J Immunol (2009) 0.92
Rapid purification and scale-up of honokiol and magnolol using high-capacity high-speed counter-current chromatography. J Chromatogr A (2007) 0.92
Inhibition of human peptide deformylase disrupts mitochondrial function. Mol Cell Biol (2010) 0.91
Structure and activity of human mitochondrial peptide deformylase, a novel cancer target. J Mol Biol (2009) 0.91
C-Galactosylceramide Diastereomers via Sharpless Asymmetric Epoxidation Chemistry. Tetrahedron (2008) 0.90
Synthesis of both possible isomers of the northwest quadrant of altromycin B. J Org Chem (2003) 0.90
Isolation of carbohydrate-specific CD4(+) T cell clones from mice after stimulation by two model glycoconjugate vaccines. Nat Protoc (2012) 0.90
Characterization of the catalytic activity of the membrane-anchored metalloproteinase ADAM15 in cell-based assays. Biochem J (2009) 0.89
Synthesis and human NKT cell stimulating properties of 3-O-sulfo-alpha/beta-galactosylceramides. Bioorg Med Chem (2005) 0.89
Generation of tissue-specific H-2Kd transgenic mice for the study of K(d)-restricted malaria epitope-specific CD8+ T-cell responses in vivo. J Immunol Methods (2012) 0.88
A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS One (2013) 0.87
Abundance and community of snow bacteria from three glaciers in the Tibetan Plateau. J Environ Sci (China) (2010) 0.87
The role of natural killer T cells and other T cell subsets against infection by the pre-erythrocytic stages of malaria parasites. Microbes Infect (2003) 0.87
Demonstration of microtubule-like structures formed with (-)-rhazinilam from purified tubulin outside of cells and a simple tubulin-based assay for evaluation of analog activity. Arch Biochem Biophys (2009) 0.86
A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity. Semin Immunol (2009) 0.86
Confirmation of the Structures of Synthetic Derivatives of Migrastatin in the Light of Recently Disclosed Crystallographically Based Claims. Tetrahedron Lett (2010) 0.85
A multifactorial mechanism in the superior antimalarial activity of alpha-C-GalCer. J Biomed Biotechnol (2009) 0.84
Functional invariant NKT cells in pig lungs regulate the airway hyperreactivity: a potential animal model. J Clin Immunol (2010) 0.81
A Weinreb nitrile oxide and nitrone for cycloaddition. Org Lett (2004) 0.81
An 19F magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: proof of principle. Clin Cancer Res (2005) 0.79
Isolation and purification of ginkgo flavonol glycosides from Ginkgo biloba leaves by high-speed counter-current chromatography. J Sep Sci (2007) 0.78
Effects of HIV-1-induced CD1c and CD1d modulation and endogenous lipid presentation on CD1c-restricted T-cell activation. BMC Immunol (2013) 0.78
Effects of winter covering crop residue incorporation on CH₄ and N₂O emission from double-cropped paddy fields in southern China. Environ Sci Pollut Res Int (2015) 0.77
Peripheral blood invariant natural killer T cells of pig-tailed macaques. PLoS One (2012) 0.76
Synthesis of the Mixed Acetal Segment of S-Glyceroplasmalopsychosine. Tetrahedron (2008) 0.75
Circumsporozoite protein as a potential target for antimalarials. Expert Rev Anti Infect Ther (2015) 0.75
A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra. Mol Cancer Ther (2003) 0.75
A novel neoglycopeptide building block. Bioorg Med Chem (2003) 0.75
The Ramberg-Bäcklund reaction for the synthesis of C-glycosides, C-linked-disaccharides and related compounds. Carbohydr Res (2006) 0.75
The synthesis and biological evaluation of novel bridging nucleoside analogues. Bioorg Med Chem (2002) 0.75